A novel antimalarial treatment based on engineered antibodies
The treatment of malaria has been hampered by the appearance of parasites resistant to conventional malaria drugs. Disease progression relies on the adherence of parasite-containing red blood cells to the blood vessel tissues. This condition allows the parasite to evade its clearance from the blood. Current treatments focus on killing the parasites inside of infected red blood cells but resistant strains have evolved with the ability to pump the drugs out of the erythrocytes.
